German biotech MorphoSys said last week that it has signed an agreement with the University of Melbourne to jointly investigate new therapeutic applications for MOR103, MorphoSys' HuCAL antibody currently in development for treating rheumatoid arthritis.

Under the terms of the agreement, MorphoSys will fund research activities at the University of Melbourne in multiple new indications. The university will receive an undisclosed upfront payment and will be entitled to research funding and clinical milestone and royalty payments, MorphoSys said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.